TABLE 5.

Adjusted regression model using stepwise selection at the baseline visit^a

Outcome variable	Adjusted model Ab		Adjusted model Bc
	OR (95% CI)	P valued	OR (95% CI)	P valued
Bedroom	2.21 (0.93–5.26)	0.07	2.07 (0.91–4.73)	0.08
HH size (no. of people)
1–2	5.06 (1.14–22.34)	0.03*	4.98 (1.00–24.87)	0.05*
3	1.20 (0.30–4.75)	0.79	0.52 (0.13–2.13)	0.36
4	7.20 (0.70–73.19)	0.09	2.75 (0.46–16.62)	0.26
≥5	Ref	Ref	Ref	Ref
House type
Attached	Ref	Ref
Single family	1.31 (0.34–5.00)	0.69
Apartment	6.29 (0.80–49.63)	0.08
Domestic pets	1.23 (0.97–1.57)	0.09	1.31 (1.08–1.60)	0.01*
Season
Summer			Ref	Ref
Fall			1.41 (0.25–8.02)	0.70
Winter			3.28 (0.61–17.62)	0.16
Spring			1.48 (0.34–6.48)	0.60
HH Abx use
No use	Ref	Ref
Human and pet use	63.80 (1.50–2,718.77)	0.03*
Individual Abx use
Clinda			0.27 (0.09–0.79)	0.02*
Sulfa			2.39 (0.74–7.73)	0.14

^aData are for 104 isolates. HH, household; Abx, antimicrobial; Clinda, clindamycin; Sulfa, trimethoprim-sulfamethoxazole; Ref, reference group.

^bModel A evaluates any use of antimicrobial drugs by human or domestic animal occupants.

^cModel B evaluates mupirocin, clindamycin, and trimethoprim-sulfamethoxazole use as individual variables.

^dSignificance, indicated in bold, is as follows: *, P ≤ 0.05.